Abiraterone plus prednisone alone or with dasatinib in chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC).
Tanya B. Dorff
Consultant or Advisory Role - Janssen
Research Funding - Bristol-Myers Squibb
Susan G. Groshen
No relevant relationships to disclose
David I. Quinn
Consultant or Advisory Role - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Genentech; Janssen; Medivation; Novartis; Prometheus
Honoraria - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Genentech; Janssen; Medivation; Novartis; Pfizer; Prometheus
Research Funding - Millennium; Sanofi
Expert Testimony - Medivation; Teva
Amir Goldkorn
Research Funding - Janssen Biotech
Cynthia L. Martel
No relevant relationships to disclose
Jacek K. Pinski
Honoraria - Janssen Pharmaceutical
Peter Kuhn
No relevant relationships to disclose
Mitchell E. Gross
No relevant relationships to disclose